Header Logo

Connection

DAVID POPLACK to Antineoplastic Agents

Back to Details
This is a "connection" page, showing publications DAVID POPLACK has written about Antineoplastic Agents.
DAVID POPLACK
Connection Strength
1.643
Antineoplastic Agents
  1. Intrathecal mafosfamide: a preclinical pharmacology and phase I trial. J Clin Oncol. 2005 Mar 01; 23(7):1555-63.
    View in: PubMed
    Score: 0.127
  2. New cytotoxic drugs for intrathecal administration. J Neurooncol. 1998 Jun-Jul; 38(2-3):219-23.
    View in: PubMed
    Score: 0.080
  3. Impact of nutrition on pharmacokinetics of anti-neoplastic agents. Int J Cancer Suppl. 1998; 11:48-51.
    View in: PubMed
    Score: 0.077
  4. Pharmacologic strategies for the treatment of meningeal malignancy. Invest New Drugs. 1996; 14(1):69-85.
    View in: PubMed
    Score: 0.067
  5. Pharmacokinetics, cerebrospinal fluid penetration, and metabolism of piroxantrone in the rhesus monkey. Invest New Drugs. 1993 Nov; 11(4):255-61.
    View in: PubMed
    Score: 0.058
  6. Phase I study of high-dose piroxantrone with granulocyte colony-stimulating factor. J Clin Oncol. 1993 Sep; 11(9):1795-803.
    View in: PubMed
    Score: 0.057
  7. Cerebrospinal fluid pharmacokinetics and toxicology of intraventricular and intrathecal arabinosyl-5-azacytosine (fazarabine, NSC 281272) in the nonhuman primate. Invest New Drugs. 1993 May-Aug; 11(2-3):135-40.
    View in: PubMed
    Score: 0.056
  8. Mechanism of resistance to cyclopentenyl cytosine (CPE-C) in Molt-4 lymphoblasts. Biochem Pharmacol. 1993 Apr 06; 45(7):1493-501.
    View in: PubMed
    Score: 0.056
  9. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res. 1993 Mar 01; 53(5):1032-6.
    View in: PubMed
    Score: 0.055
  10. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer Res. 1993 Feb 15; 53(4):725-7.
    View in: PubMed
    Score: 0.055
  11. Pharmacokinetics of PEG-L-asparaginase and plasma and cerebrospinal fluid L-asparagine concentrations in the rhesus monkey. Cancer Chemother Pharmacol. 1993; 32(4):310-4.
    View in: PubMed
    Score: 0.055
  12. Pediatric phase I trial, pharmacokinetic study, and limited sampling strategy for piritrexim administered on a low-dose, intermittent schedule. Cancer Res. 1992 Feb 01; 52(3):521-4.
    View in: PubMed
    Score: 0.051
  13. Pharmacokinetics of pyrazoloacridine in the rhesus monkey. Cancer Res. 1991 Oct 15; 51(20):5467-70.
    View in: PubMed
    Score: 0.050
  14. Current pharmacological treatment approaches to central nervous system leukaemia. Drugs. 1991 May; 41(5):702-16.
    View in: PubMed
    Score: 0.049
  15. Development of chemotherapy treatment for pediatric brain tumors. Neurol Clin. 1991 May; 9(2):363-73.
    View in: PubMed
    Score: 0.049
  16. Pediatric phase I trial and pharmacokinetic study of piritrexim administered orally on a five-day schedule. Cancer Res. 1990 Aug 01; 50(15):4464-7.
    View in: PubMed
    Score: 0.046
  17. Central nervous system pharmacology of antileukemic drugs. Am J Pediatr Hematol Oncol. 1989; 11(1):74-86.
    View in: PubMed
    Score: 0.041
  18. Preclinical pharmacology of arabinosyl-5-azacytidine in nonhuman primates. Cancer Res. 1988 Aug 01; 48(15):4294-8.
    View in: PubMed
    Score: 0.040
  19. A pediatric phase I and pharmacokinetic study of spirohydantoin mustard. Cancer Res. 1988 Apr 15; 48(8):2292-5.
    View in: PubMed
    Score: 0.039
  20. Intrathecal administration of 4-hydroperoxycyclophosphamide in rhesus monkeys. Cancer Res. 1987 Nov 15; 47(22):5932-4.
    View in: PubMed
    Score: 0.038
  21. Pharmacokinetics of tiazofurin in the plasma and cerebrospinal fluid of rhesus monkeys. Cancer Res. 1985 May; 45(5):2037-9.
    View in: PubMed
    Score: 0.032
  22. Cerebrospinal fluid pharmacokinetics of intraventricular and intravenous aziridinylbenzoquinone. Cancer Res. 1984 Apr; 44(4):1698-701.
    View in: PubMed
    Score: 0.030
  23. Intrathecally administered m-AMSA in the rhesus monkey. Cancer Drug Deliv. 1984; 1(2):101-7.
    View in: PubMed
    Score: 0.029
  24. Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol. 2003 Jan 01; 21(1):143-7.
    View in: PubMed
    Score: 0.027
  25. Treatment of acute lymphoblastic leukemia in relapse: efficacy of a four-drug reinduction regimen. Cancer Treat Rep. 1981; 65 Suppl 4:93-6.
    View in: PubMed
    Score: 0.024
  26. Ability of a new antitumor agent, AZQ, to penetrate into cerebrospinal fluid. Pharmacology. 1981; 22(3):196-8.
    View in: PubMed
    Score: 0.024
  27. Pregnancy outcome following cancer chemotherapy. Am J Med. 1980 Dec; 69(6):828-32.
    View in: PubMed
    Score: 0.024
  28. Improved treatment results in the management of single and multiple relapses of acute lymphoblastic leukemia. Cancer. 1980 Jun 15; 45(12):3090-4.
    View in: PubMed
    Score: 0.023
  29. Pharmacokinetics of ICRF-187 in the cerebrospinal fluid of subhuman primates. Cancer Treat Rep. 1980 Apr-May; 64(4-5):734-6.
    View in: PubMed
    Score: 0.023
  30. Adrenal suppression after short-term corticosteroid therapy. Lancet. 1979 Mar 24; 1(8117):630-3.
    View in: PubMed
    Score: 0.021
  31. Hypothalamic-pituitary dysfunction following CNS prophylaxis in acute lymphocytic leukemia: correlation with CT scan abnormalities. Med Pediatr Oncol. 1979; 7(2):141-51.
    View in: PubMed
    Score: 0.021
  32. The Ommaya reservoir: newly recognized complications and recommendations for insertion and use. Cancer. 1978 Jun; 41(6):2431-7.
    View in: PubMed
    Score: 0.020
  33. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. Clin Cancer Res. 1998 Feb; 4(2):357-60.
    View in: PubMed
    Score: 0.019
  34. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers. J Clin Oncol. 1998 Jan; 16(1):181-6.
    View in: PubMed
    Score: 0.019
  35. Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer. 1996 Aug 01; 78(3):527-31.
    View in: PubMed
    Score: 0.018
  36. Central nervous system leukemia. Curr Opin Oncol. 1996 Jan; 8(1):13-9.
    View in: PubMed
    Score: 0.017
  37. Advances in the treatment of meningeal cancers. Crit Rev Oncol Hematol. 1995 Aug; 20(1-2):87-98.
    View in: PubMed
    Score: 0.016
  38. Intrathecal administration of topotecan in nonhuman primates. Cancer Chemother Pharmacol. 1995; 36(2):121-4.
    View in: PubMed
    Score: 0.016
  39. Pharmacokinetics of piroxantrone in a phase I trial of piroxantrone and granulocyte-colony stimulating factor. Cancer Res. 1993 Jun 01; 53(11):2587-90.
    View in: PubMed
    Score: 0.014
  40. Pharmacologic approaches to the treatment of meningeal malignancy. Oncology (Williston Park). 1991 May; 5(5):107-16; discussion 123, 127.
    View in: PubMed
    Score: 0.012
  41. Pharmacology and drug resistance in childhood lymphoblastic leukemia. Hematol Oncol Clin North Am. 1990 Oct; 4(5):871-94.
    View in: PubMed
    Score: 0.012
  42. A rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid. Lab Anim Sci. 1990 Sep; 40(5):520-5.
    View in: PubMed
    Score: 0.012
  43. Expression of the mdr-1/P-170 gene in patients with acute lymphoblastic leukemia. Blood. 1989 Sep; 74(4):1388-95.
    View in: PubMed
    Score: 0.011
  44. Testicular function in boys after chemotherapy for acute lymphoblastic leukemia. N Engl J Med. 1981 May 07; 304(19):1121-4.
    View in: PubMed
    Score: 0.006
  45. Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma. Am J Med. 1980 Apr; 68(4):486-91.
    View in: PubMed
    Score: 0.006
  46. Experimental approaches to the treatment of CNS leukemia. Am J Pediatr Hematol Oncol. 1979; 1(2):141-9.
    View in: PubMed
    Score: 0.005
  47. Neurotoxicities of current leukemia therapy. Am J Pediatr Hematol Oncol. 1979; 1(2):127-40.
    View in: PubMed
    Score: 0.005
  48. Combined modality treatment of Burkitt's lymphoma. Cancer Treat Rep. 1978 Dec; 62(12):2031-4.
    View in: PubMed
    Score: 0.005
  49. Leukoencephalopathy following chemotherapy for rhabdomyosarcoma: reversibility of cerebral changes demonstrated by computed tomography. J Pediatr. 1977 Jul; 91(1):77-9.
    View in: PubMed
    Score: 0.005
  50. Late soft tissue recurrence of acute lymphoblastic leukemia in a site of antecedent trauma. J Pediatr. 1978 May; 92(5):849-50.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.